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The prevalence of overactive bladder (OAB) increases with age. Degeneration of the central nervous
system in the elderly has been proposed as one of the pathogenic factors of OAB. Antimuscarinic therapy
is effective in the treatment of OAB; however, intolerable systemic adverse events and cognitive
dysfunction during treatment with nonselective antimuscarinic agents is of growing concern in elderly
patients. The newly developed beta-3 adrenoceptor agonist mirabegron does not adversely affect ﬂow
rate and detrusor pressure, and its therapeutic efﬁcacy and tolerability are similar in patients aged >
65 years and > 75 years, suggesting it might be the therapeutic choice in older patients with OAB.
Nocturia can cause sleep deprivation at night and increase daytime sleepiness and loss of energy in the
elderly. Desmopressin add-on therapy is effective in improving nocturia and storage symptoms. How-
ever, elderly patients with a baseline serum sodium level below the normal range are at high risk of
developing signiﬁcant hyponatremia.
Copyright © 2016, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Prevalence of overactive bladder in the elderly
Overactive bladder (OAB) is a clinical diagnosis with the core
symptom of urgency, accompanied by frequency and nocturia, with
or without urgency urinary incontinence [1]. The strongest pre-
dictor of OAB-associated bother is urinary urgency [2]. OAB
symptoms can be bothersome and can negatively affect health-
related quality of life (HR-QoL) [3,4]. Because the prevalence of
OAB increases with age, identifying and treating OAB in the elderly
is important [5,6]. Several medical comorbidities may have asso-
ciations with urinary storage symptoms [7]. The risk of nocturnal
polyuria also increases in patients aged  65 years [8].
In one study, patients with congestive heart failure had more
storage urinary symptoms suggestive of OAB than age-matched
controls [9]. Another study demonstrated that patients with
congestive heart failure had high OAB symptom scores and storage
International Prostate Symptom Scores (IPSSs) suggestive of OAB
and/or storage lower urinary tract symptoms (LUTSs) [10,11].ddhist Tzu Chi General Hos-
. Tel.: þ886 3 8561825x2117;
lief Tzu Chi Foundation. PublishedDiabetes mellitus (DM) is a chronic metabolic condition and
causes numerous complications. Clinicians have become concerned
about OAB and its component symptoms [12,13]. Patients with type
2 DM present with more OAB symptoms such as urgency and
nocturia than controls. The effects of diabetes due to poor blood
sugar control as measured by glycated hemoglobin could play a
crucial role in the development of OAB symptoms [14]. In a recent
study, Wen et al [15] found that DM patients with a body mass
index > 25 and obesity were more likely to have OAB than those
without these conditions. Chapple et al [16] reported that 21.4% of
3962 diabetic women had OAB. Some patients have both detrusor
overactivity (DO) and inadequate contractility, resulting in urgency
urinary incontinence and a large postvoid residual volume (PVR)
[17]. Different urodynamic ﬁndings of low detrusor contractility
with or without increased isovolumetric contractions have also
been found in women with idiopathic underactive bladder [18].2. Pathophysiology of OAB in the elderly
OAB is common in both sexes and increases in prevalence with
aging. Animal and human studies have revealed that increased
release of acetylcholine from nonneuronal and neuronal sources
during bladder ﬁlling causes OAB and DO, and this afferent activity
can be inhibited by antimuscarinics [19]. In addition, increasedby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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in the urotheliumof aged bladdersmight alter the afferent pathway,
resulting in OAB in the older population [20]. Chronic ischemia and
inﬂammation in the aged bladder might also contribute to bladder
dysfunction in the elderly [21]. In patients with DM, the PVR is
signiﬁcantly increased, which might increase the bother of voiding
dysfunction in addition to OAB in the elderly [22].
3. Neurological disease in OAB elderly patients
The incidence of OAB increases with aging; thus, degeneration
of the central nervous system (CNS) in the elderly is proposed as
one of the pathogenic factors of OAB [23]. In patients with CNS
disorders such as cerebrovascular accident and Parkinson's disease
(PD), white matter disease causing dementia increases signiﬁcantly
with age and can also cause OAB and urinary incontinence [24]. A
random-effect meta-analysis found that the prevalence of urinary
incontinence was 50.9% in patients with multiple sclerosis, 52.3% in
those with spinal cord injury, 33.1% in those with PD, and 23.6% in
stroke patients [25].
In patients older than 60 years with irritative urinary symptoms,
brain magnetic resonance image showed subclinical high-intensity
ischemic changes in the basal ganglia in 82.6% of elderly OAB pa-
tients [26]. OAB is common in elderly people with CNS lesions. In a
community health survey, 31% of patients with CNS disease re-
ported OAB symptoms, and the overall prevalence of neurogenic
OAB was 0.6%. Patients with neurogenic OAB have a poorer HR-QoL
compared with patients with general OAB [27].
Anticholinergic treatment of OAB in patients with CNS lesions
could cause CNS adverse events (AEs) and impaired bladder
emptying. Although antimuscarinic treatment has a high success
rate, cognitive dysfunction during treatment with nonselective
antimuscarinic agents for OAB is of growing concern [28]. In the
past decade, intravesical injection of onabotulinumtoxinA (BoNT-A)
has emerged as an effective treatment for OAB among patients
refractory to or intolerant of antimuscarinic agents [29]. BoNT-A
signiﬁcantly improves OAB symptoms and urodynamic parame-
ters in neurogenic DO and OAB. However, increased PVR and risk of
urinary tract infection after BoNT-A treatment remain concerns
among frail elderly patients [30]. If patients wish to be completely
dry and avoid an indwelling catheter, clean intermittent catheter-
ization to periodically empty the patient's bladder should be taught
to the caregiver. All OAB patients with cerebrovascular accident, PD,
or dementia should be informed of possible AEs and bladder
management strategy prior to institution of BoNT-A treatment.
4. Antimuscarinic therapy and response in the elderly with or
without benign prostatic hyperplasia
First-line treatment for OAB should start with lifestyle modiﬁ-
cation, followedby the second-line pharmacotherapy [31]. Themost
commonly used antimuscarinic agents for OAB are oxybutynin,
tolterodine, solifenacin, darifenacin, fesoterodine, and trospium.
These antimuscarinics have proven effective in decreasing urgency,
urgency incontinence, and nocturia episodes [32].
Multiple studies have suggested that antimuscarinic therapy
alone or in combination with alpha1-receptor antagonists im-
proves OAB symptoms in men with and without bladder outlet
obstruction (BOO) [33e35]. Therefore, a deeper understanding of
the pathophysiology of OAB that underlies male LUTS, and exami-
nation of the relationship between symptoms and urodynamic
ﬁndings are needed in the diagnosis and treatment of male LUTS
associated with OAB [36].
Antimuscarinics were previously considered contraindicated in
patients with benign prostatic hyperplasia (BPH) or BOO [37].Because the symptoms of BPH and OAB overlap, antimuscarinics
with or without a blockers appear to be an effective and safe
alternative for male storage symptoms in men with BPH and
without an elevated PVR volume [35,37e39]. However, anti-
muscarinics are usually reserved as second-line medication in men
with OAB because of fears of precipitating urinary retention.
There is still controversyaboutwhichBPHpatients are suitable for
ﬁrst-line antimuscarinic monotherapy. Current guidelines suggest
that antimuscarinicmonotherapy can be used for menwithout BOO,
whereas combination therapy is usually suggested for men with
concomitant BOO and OAB [40,41]. However, determining the pres-
ence and the degree of BOO is occasionally difﬁcult without a pres-
sureﬂow study. Uroﬂowmetry and PVRmeasurement are commonly
used parameters, but there is still no deﬁnite cutoff value indicating
which patients are suitable for antimuscarinic monotherapy.
We reported that using IPSS subscores that measure and
calculate the IPSS voiding-to-storage subscore ratio is a simple and
useful method to differentiate failure to voiding and failure to
storage lower urinary tract dysfunction [42]. Our previous results
showed that ﬁrst-line antimuscarinic monotherapy is safe and
effective for menwith enlarged prostates and predominant storage
symptoms. A small total prostatic volume, high maximum ﬂow
rate, and high IPSS-S subscore are predictors of successful ﬁrst-line
antimuscarinic monotherapy [43].
5. AEs with antimuscarinic treatment are common in the
elderly
Antimuscarinic therapy with or without lifestyle modiﬁcation is
the most common treatment for patients with OAB. However,
several drug-related AEs, such as dry mouth, cognitive impairment,
constipation and sleep disturbance, can develop, especially in older
patients [44]. In a survey of OAB treatment results in Japan, only
32.3% of patients were satisﬁed with their treatment, and 33.1%
were dissatisﬁed. Among the AEs, constipation negatively inﬂu-
enced patient satisfaction more than dry mouth did [45]. AEs from
antimuscarinic therapy were reported in 46.8% of patients in a
recent long-term study of combined solifenacin and tamsulosin
treatment for menwith both storage and voiding LUTSs [46]. These
AEs might result in discontinuation or inadequate dose treatment
of elderly OAB patients. Clinicians should use caution in prescribing
antimuscarinics in frail elderly patients. The potential adverse CNS
events of each anticholinergic agent must be weighed against the
severity of OAB symptoms [47].
Many anticholinergics can cross the bloodebrain barrier and
cause CNS effects such as cognitive impairment [48]. Cognitive
impairment is a serious concern in antimuscarinic therapy for
elderly patients with OAB. Oxybutynin is often recommended in
guidelines, but it is associated with a high incidence of cognitive
impairment, and is therefore not recommended for use in frail older
OAB patients [49].
A study of persistence with solifenacin add-on therapy after
tamsulosin monotherapy in men with BPH and residual OAB
revealed that only 25% of men remained on solifenacin therapy
after 1 year. The reasons for discontinuationwere AEs in 35%, lack of
efﬁcacy in 33%, and improvement in symptoms in 16% [50]. A
systemic review of persistence and adherence to treatment of OAB
with anticholinergic therapy revealed that 43e83% of patients
discontinued medication within the ﬁrst 30 days and rates
continued to rise over time [51]. The persistence rate for anti-
muscarinics depends on the drug used. In a UK survey, patients
aged 60 years and older were more likely to persist with prescribed
oral antimuscarinic drugs (solifenacin) than younger patients [52].
The proportion of patients who were adherent during anti-
muscarinic treatment was 60.4% [53].
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piverine had the least favorable relationship between efﬁcacy and
AEs [54]. Oxybutynin was associated with signiﬁcant decreases in
the cognitive functions of power and continuity of attention [55].
Flexible dosing with fesoterodine by escalating from low to high
doses signiﬁcantly improved OAB symptoms and AEs in vulnerable
community-dwelling individuals who are older than 75 years,
similar to younger populations [56]. The adherence rate of anti-
muscarinic therapy might be drug-speciﬁc. In elderly patients, it is
better to start with a low dose of appropriate antimuscarinics and
gradually escalate to a tolerable and effective dose.
6. Can a second antimuscarinic be used for refractory OAB
symptoms in the elderly?
If a patient experiences inadequate symptom control and/or
unacceptable AEs with one antimuscarinic, then a dose modiﬁca-
tion or a different antimuscarinic medicationmay be tried [57]. One
study proved that additive treatment with extended-release (ER)
tolterodine is a beneﬁcial and safe therapeutic option in older men
with BPH/BOO and storage symptoms treated with alpha blockers
and/or 5-alpha-reductase inhibitors [58]. Several recent trials also
proved that adding antimuscarinics to an alpha blocker provided
efﬁcacy in improvement of residual OAB symptoms in men with
LUTSs [33e35,59].
In elderly women with severe OAB, a combination of two very
high-dose antimuscarinics (40 mg solifenacin þ 60 mg trospium)
was effective in reducing OAB recurrence in maintenance therapy
for 7 months [60]. A recent clinical trial showed that combination
therapy with mirabegron (25 mg or 50 mg) and different doses of
solifenacin signiﬁcantly increased the maximal voided volume and
reduced frequency and urgency episodes compared with sol-
ifenacin monotherapy [61].
Combined antimuscarinic and alpha blocker treatment is
generally more effective than monotherapy or placebo. Studies
have proved that combination therapy with tolterodine-ER and
tamsulosin is signiﬁcantly more effective than placebo or tamsu-
losin monotherapy in the treatment of men with OAB and BPH
[62,63]. In elderly men with BPH and OAB, a combination of an
alpha blocker and antimuscarinic was safe and effective in
improving LUTSs in the short term without increasing PVR and
urinary retention [64].
7. Mirabegron is safe in elderly OAB patients without
increasing the risks of a large PVR or acute urinary retention
Mirabegron, a b3-adrenoceptor agonist, is the ﬁrst of this class of
drugs for the treatment of OAB [65]. Mirabegron has demonstrated
signiﬁcant dose-dependent improvements in key OAB symptoms. A
dose ranging study showed that 50 mg mirabegron once daily is
most promising for clinical OAB [66]. OAB patients who are either
antimuscarinic treatment naïve or have received prior anti-
muscarinic treatment could beneﬁt from mirabegron treatment in
reducing the frequency of micturition and incontinence episodes
[67]. Pooled safety data indicated that mirabegron is a valuable
treatment option for patients with OAB as the incidence of dry
mouth, the chief cause of discontinuation of antimuscarinic agents,
was lower than with tolterodine ER (4 mg) [68].
Recent Phase III trials have conﬁrmed the efﬁcacy and safety of
mirabegron in treatment of OAB [69e73]. A urodynamic study in
menwith OAB and BOO revealed that mirabegron did not adversely
affect the maximum ﬂow rate (Qmax) and detrusor pressure at Qmax
after 12 weeks of treatment [74]. The incidence of bothersome
antimuscarinic AEs such as dry mouth with mirabegron was at
placebo level, and of a lower magnitude (6-fold less) thantolterodine [68,75]. The therapeutic efﬁcacy and tolerability of
mirabegron showed no signiﬁcant difference between patients
aged > 65 years and > 75 years, supporting that mirabegron might
be the therapeutic choice in elderly OAB patients [75]. The evidence
suggests that mirabegron might provide a safe way to get rid of
diapers in elderly OAB patients without increasing the risks of a
large PVR or acute urinary retention. Reported AEswithmirabegron
are rare [69e73]. However, hypertension and tachycardia in elderly
OAB patients who have cardiovascular disease still require careful
monitoring after long-term treatment.
8. Nocturnal polyuria remains an important cause of OAB in
the elderly
Nocturia is deﬁned as wakening from sleep one ormore times to
void. Nocturia is the most common core LUTS in the elderly, and is
reported in 29.9% of menwith LUTS [76]. The prevalence of nocturia
is high in both sexes and increases with age [77]. Nocturia may be
caused by nocturnal polyuria and reduced bladder capacity, alone
or in combination, and polyuria [78]. Urodynamic study of patients
with nocturia revealed DO incontinence in 26% of women and DO
in 64% of men. Nocturnal polyuriawas noted in 55% of patients with
nocturia [78]. Nocturia may cause sleep deprivation at night and
increase daytime sleepiness and loss of energy, which may have a
great impact on HR-QoL in the elderly [79].
Aging is an important risk factor for nocturia. The nocturnal
polyuria index increases signiﬁcantly with age. Reduced bladder
capacity and increased nocturnal urine output are important in the
pathogenesis of nocturia in the elderly [80]. Nocturnal polyuria in
the elderly is known to be caused by an age-related change in the
circadian rhythm of arginine vasopressin secretion [81]. Nocturia in
older men with LUTSs might also result from DO due to BOO and
increased bladder oversensitivity. Nocturia and frequency are noted
to correlate inversely with the maximum cystometric bladder ca-
pacity [82,83]. Nocturia and enuresis are also important symptoms
of a sleep disorder. The nocturnal polyuria of sleep apnea is an
evoked response to conditions of negative intrathoracic pressure
owing to inspiratory effort posed against a closed airway [84].
Nocturia is frequently seen in obese elderly men. Nocturnal poly-
uria with abnormal circadian rhythm of plasma arginine vaso-
pressin has also been noted in poststroke patients [85].
Desmopressin signiﬁcantly increases the osmolality of nighttime
urine in elderly patients with nocturnal polyuria [86]. A double-
blind, placebo-controlled study in men with nocturia revealed
34% of the desmopressin group had fewer than half the number of
nocturnal voids compared with baseline [87]. The duration of the
ﬁrst sleep period also increased in the desmopressin group, which
signiﬁcantly improved the quality of sleep versus placebo [88].
Desmopressin add-on therapy is also effective in improving noc-
turia and storage symptoms in men receiving an alpha blocker for
LUTSs [89].
Although desmopressin is effective in decreasing nocturnal
voids in elderly patients, the safety in patients older than 65 years is
a great concern. Hyponatremia might develop in the patients tak-
ing vasopressin [87,90]. Elderly patients (> 65 years) with a baseline
serum sodium level below the normal range are at high risk (75%)
of developing signiﬁcant hyponatremia [91]. Long-term desmo-
pressin treatment gradually decreased the serum Na concentration
and induced signiﬁcant hyponatremia in patients who did not have
initial hyponatremia. After discontinuing desmopressin, the serum
sodium returned to the normal level. In addition, desmopressin
treatment for 1 year in elderly patients did not affect the baseline
endogenous antidiureic hormone level [92]. Therefore, assessment
of the serum sodium level is necessary at least every 6 months in
elderly patients receiving long-term vasopressin treatment.
J.-L. Chen et al. / Tzu Chi Medical Journal 28 (2016) 1e549. Conclusions
Elderly patients might have medical and neurological diseases
that increase their vulnerability in the management of urination.
Although antimuscarinic therapymay improve OAB symptoms, AEs
are common in the elderly. A new class of drug for OAB, the beta-3
adrenoceptor agonist mirabegron, may provide a safe treatment for
elderly OAB patients without increasing the risks of a large PVR.
Clinicians should be aware of the balance between therapeutic ef-
ﬁcacy and safety in the treatment of OAB in the elderly.
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